Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2773048 | 0.90 | PTGDR2 (0.47) | ACLYPTGDR2MAPTFFAR1 | |
| SCHEMBL13160866 | 0.89 | PTGDR2 (0.47) | PTGDR2PTPN1MAPTALDH1A1LMNA | |
| SCHEMBL2773506 | 0.88 | PTGDR2 (0.51) | PTGDR2PTPN1MAPTALDH1A1LMNA | |
| SCHEMBL2771520 | 0.87 | PTGDR2 (0.55) | PTGDR2PTPN1 | |
| SCHEMBL13161562 | 0.87 | PTGDR2 (0.45) | PTGDR2PTPN1MAPT | |
| SCHEMBL2773773 | 0.87 | PTGDR2 (0.57) | PTGDR2PTPN1 | |
| SCHEMBL2770575 | 0.87 | PTGDR2 (0.47) | PTGDR2PTPN1MAPTTP53 | |
| SCHEMBL2772422 | 0.87 | PTGDR2 (0.48) | PTGDR2MAPTALDH1A1LMNA | |
| SCHEMBL2771155 | 0.86 | PTGDR2 (0.57) | PTGDR2PTPN1MAPTALDH1A1LMNA | |
| SCHEMBL2771016 | 0.86 | PTGDR2 (0.52) | PTGDR2PTPN1MAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822467-B2 | Biaryl oxyacetic acid compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | claimed |
| US-20130102609-A1 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INC. (US) | 2013-04-25 | — | — | US | claimed |
| WO-2010102154-A2 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-09-10 | — | — | WO | claimed |
| US-8822467-B2 | Biaryl oxyacetic acid compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822467-B2 | Biaryl oxyacetic acid compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822467-B2 | Biaryl oxyacetic acid compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130102609-A1 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102609-A1 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102609-A1 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INC. (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2010102154-A2 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102609-A1 | BIARYL OXYACETIC ACID COMPOUNDS | HSD17B12, CYP2A13, CYP27A1 | ACLY 1166/4885PTGDR2 377/4885PTPN1 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.